Docoh
Loading...

GSK Glaxosmithkline

Filed: 12 Oct 21, 11:00am
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of October 2021
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
 
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Ms E Walmsley
 
b)Position/status
Chief Executive Officer
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938931 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 

 1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Mr R Connor
 
b)Position/status
President, Vaccines & Global Health
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938989 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Ms D Conrad
 
b)Position/status
SVP, Human Resources
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.93896 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Mr J Ford
 
b)Position/status
SVP & General Counsel
 
c)
Initial notification/amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.93894 
    
d)Aggregated information
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Ms S Jackson
 
b)Position/status
SVP, Global Communications and CEO Office
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938982 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Mr D Jackson
 
b)Position/status
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938932 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Mr L Miels
 
b)Position/status
Chief Commercial Officer
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.93895 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 

1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Mr D Redfern
 
b)Position/status
Chief Strategy Officer
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.9389100 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Mr R Simard
 
b)Position/status
President, Pharmaceuticals Supply Chain
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938931 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Mr P Thomson
 
b)Position/status
President, Global Affairs
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938960 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)
Date of the transaction
 
2021-10-07
f)
Place of the transaction
 
London Stock Exchange (XLON)

 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Ms D Waterhouse
 
b)Position/status
Chief Executive Officer of ViiV Healthcare
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938980 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)

 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)Name
Ms V Whyte
 
b)Position/status
Company Secretary
 
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)Name
GlaxoSmithKline plc
 
b)LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 
b)Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £13.938974 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
 
e)Date of the transaction
2021-10-07
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: October 12, 2021 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc